한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

yuyue medical's leadership team seems to be trying to find a breakthrough. they tried to make up for the performance shortfall by increasing r&d investment and expanding overseas markets, but faced with the huge pressure of "tens of billions in revenue and hundreds of billions in market value", their actions seemed stretched. r&d funding cuts, backward product design, and all these problems put yuyue medical in a difficult situation.

in 2023, yuyue medical's r&d investment accounted for only 6%, far below the industry average. this shows that the company seems to be choosing a product route that relies on sales and marketing, while ignoring technological innovation and development.

however, we cannot simply attribute yuyue medical’s predicament to insufficient r&d. perhaps, they are also facing deeper challenges: how to balance development strategy with market demand? how to maintain rapid growth while establishing a sustainable development system?

for example, the diabetes track, as a shining star of yuyue medical, has shown its potential. however, relying solely on a "50% annual growth rate" is difficult to make up for the gaps in other sectors. even if this sector can bring in about 1.5 billion in revenue in the next few years, this is only a supplementary part and cannot support its 10 billion revenue target.

yuyue medical also faces challenges in expanding its overseas markets. although the proportion of overseas business has continued to decline in recent years, the company still insists on expanding the market scale and actively exploring new growth points. however, this strategy may also be difficult to sustain due to the market environment and pressure from competitors.

the pressure of "tens of billions in revenue and hundreds of billions in market value" seems to have become yuyue medical's biggest problem. they need to make a choice, and this decision will affect the company's development direction in the next few years, as well as investors' assessment of the company's investment value.